Cancer Pain

ATLANTA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced today that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The listing compliance matter is now closed. Below are some recent key developments in the business. Key Highlights Top-line results from the Bateman Horne Center’s phase 2a study of IMC-2 for the treatment of Long-COVID are expected to be released in mid-November 2024.Integration efforts continue following the Company’s acquisition of Pharmagesic (Holdings) Inc. in early October 2024. About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms that include a non-opioid analgesic program and an antiviral program. The proprietary non-opioid, Nav 1.7 analgesic program is centered on lead development candidate, Halneuron® which is a voltage-gated sodium channel blocker, a mechanism known to be effective for reducing pain. Halneuron® treatment has demonstrated pain reduction of both general cancer related pain and chemotherapy-induced neuropathic pain (“CINP”). Interim data from the forthcoming Phase 2 CINP study are expected in 2H 2025. The antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent, celecoxib, for the treatment of illnesses believed to be related to reactivation of previously dormant herpes viruses, including fibromyalgia (“FM”) and Long-COVID (“LC”). Top-line data from an ongoing IMC-2 Phase 2 LC study are expected in mid-November 2024. IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. For more information, please visit www.dwtx.com. Follow Dogwood Therapeutics Email Alerts: https://ir.dwtx.com/resources/email-alerts LinkedIn: https://www.linkedin.com/company/dogwoodther/ Twitter: https://twitter.com/dogwoodther Facebook: https://www.facebook.com/dogwoodther Forward-Looking Statements Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law. Contact: IR@dwtx.com

SHREVEPORT, La., Sept. 10, 2024 /PRNewswire/ -- DM Clinical Research, a prominent multi-therapeutic network of clinical trial sites, is pleased to announce its newest partnership with Dr. Jai Munjampalli and Dr. Sara Samreena to establish an embedded clinical site in Shreveport, Louisiana. Dr. Munjampalli, a neurologist and interventional pain management specialist, and Dr. Samreena, a family medicine and sleep medicine physician, are husband and wife, and together they will bring their combined expertise to this new venture. This collaboration is part of DM Clinical Research's continuing efforts to advance medical research and offer more opportunities for patients to participate in cutting-edge clinical trials. Dr. Munjampalli's practice, Brain and Pain Care, along with Dr. Samreena's Sleep Care Clinic, which operates within the same facility, will now house an embedded clinical research site, expanding the reach of DM Clinical Research in the region. The site will focus on a variety of research areas such as neurology, pain management, and sleep reflecting the couple's combined expertise and years of experience in these fields. "We are excited to partner with Dr. Munjampalli and Dr. Samreena, whose dedication to patient care and medical research aligns perfectly with our mission," said Mohammad Millwala, CEO of DM Clinical Research. "By embedding our research capabilities within their practices, we can provide patients in Shreveport and the surrounding areas with greater access to clinical trials and contribute to the development of innovative treatments that address a wide range of medical conditions." Dr. Munjampalli, originally from Hyderabad, India, brings 13 years of clinical research experience and 7 years as a practicing physician to the partnership. After earning his medical degree from Guntur Medical College, he moved to the United States in 2008, where he pursued medical training, including a residency in Neurology at LSU Health Sciences Center in Shreveport and a fellowship in Interventional Pain Management at the University of South Florida in Tampa. His clinical expertise includes the management of conditions such as cervicogenic headaches, migraines, chronic headaches, neuropathic pain, arthritic pain, and cancer-related pain. Dr. Samreena, a family medicine physician with double board certification in sleep medicine, has been practicing for 9 years. She received her medical education from Spartan Health Sciences University in St. Lucia. Dr. Samreena has extensive experience in outpatient sleep medicine, with a strong background in managing various sleep disorders, including severe insomnia, sleep apnea, and thyroid-related sleep dysfunction. "I couldn't be more excited to partner with DM Clinical Research," said Dr. Jai Munjampalli. "Clinical trials are an important care option for patients in my practice as well as all of Shreveport. We are thrilled to be a part of the DM team." With this new embedded site in Shreveport, DM Clinical Research continues to build a strong network of research sites nationwide, enhancing its ability to offer diverse and inclusive clinical trials. The company is committed to bringing innovative therapies to market and improving patient outcomes through its growing presence in communities nationwide. About DM Clinical Research DM Clinical Research is an integrated multi-therapeutic national network of clinical trial sites headquartered in Houston, Texas. Founded in 2006, the company includes 24 dedicated research centers and physician practice embedded sites, servicing a range of therapeutic areas across the nation. DM Clinical Research received the 2023 Best Clinical Trial Network Vaccine Industry Excellence Award and the Society for Clinical Research Sites 2022 Excellence in Patient Centricity Award. Through its partnerships with prominent global pharmaceutical sponsors, DM Clinical Research brings opportunities to the community to participate in cutting-edge research, under the careful medical supervision of qualified physicians and professionals. For more information, please visit dmclinical.com or call (281) 517-0550. SOURCE DM Clinical Research WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

TUESDAY, Sept. 10, 2024 -- For adults with hepatocellular carcinoma or liver metastases, low-dose liver radiotherapy plus best supportive care improve pain compared with best supportive care alone, according to a study published online Sept. 5 in The Lancet Oncology . Laura A. Dawson, M.D., from the Princess Margaret Cancer Centre at the University of Toronto, and colleagues conducted a randomized controlled phase 3 trial in nine cancer centers in Canada involving adults with hepatocellular carcinoma or liver metastases, who were refractory to standard treatment. After stratification by center and type of cancer, patients were randomly assigned to single-fraction radiotherapy (8 Gy) to the liver with 8 mg ondansetron (or equivalent) orally and 4 mg dexamethasone orally given before radiotherapy plus best supportive care or to best supportive care alone (33 patients were assigned to each group). The researchers observed an improvement in hepatic pain of at least 2 points in worst pain intensity on the Brief Pain Inventory at one month in 67 percent of 24 patients and 22 percent of 18 patients in the group receiving radiotherapy plus best supportive care and the group receiving best supportive care only, respectively. Within one month after randomization, the most common grade 3 to 4 adverse events were abdominal pain and ascites. There were no serious adverse events or treatment-related deaths reported. "Given the statistically and clinically significant reduction in pain compared with best supportive care alone at one month, this intervention could become a standard of care treatment for patients with hepatic cancer pain," the authors write. Several authors disclosed ties to the pharmaceutical industry.